Growth Metrics

Cytosorbents (CTSO) Income towards Parent Company (2016 - 2026)

Cytosorbents filings provide 15 years of Income towards Parent Company readings, the most recent being -$6.5 million for Q4 2025.

  • On a quarterly basis, Income towards Parent Company fell 256.52% to -$6.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$15.4 million, a 73.96% decrease, with the full-year FY2025 number at -$9.2 million, down 2.35% from a year prior.
  • Income towards Parent Company hit -$6.5 million in Q4 2025 for Cytosorbents, down from -$3.2 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of $15.3 million in Q4 2023 to a low of -$12.2 million in Q3 2022.
  • Median Income towards Parent Company over the past 5 years was -$5.4 million (2021), compared with a mean of -$4.4 million.
  • Biggest five-year swings in Income towards Parent Company: tumbled 1273.27% in 2021 and later skyrocketed 2102.15% in 2023.
  • Cytosorbents' Income towards Parent Company stood at -$9.3 million in 2021, then surged by 91.77% to -$766126.0 in 2022, then skyrocketed by 2102.15% to $15.3 million in 2023, then crashed by 72.91% to $4.2 million in 2024, then plummeted by 256.52% to -$6.5 million in 2025.
  • The last three reported values for Income towards Parent Company were -$6.5 million (Q4 2025), -$3.2 million (Q3 2025), and -$4.2 million (Q2 2025) per Business Quant data.